Guidelines for Stability Studies of Vaccine Products

1) Purpose

The purpose of this SOP is to outline the procedures and guidelines for conducting stability studies on vaccine products. These studies are critical to ensuring that vaccines maintain their efficacy, safety, and quality throughout their shelf life under specified storage conditions. The stability studies will assess various factors such as temperature, humidity, light exposure, and time to determine the product’s shelf life and storage requirements.

2) Scope

This SOP applies to all vaccine products manufactured, tested, and stored by the organization, including but not limited to live attenuated, inactivated, subunit, and conjugate vaccines. It encompasses all stages of vaccine development, from initial formulation to commercial batch production. It is intended for use by all personnel involved in the design, conduct, and evaluation of vaccine stability studies.

3) Responsibilities

Study Director: Responsible for designing the study, preparing the protocol, and ensuring

compliance with the SOP and regulatory guidelines.

Quality Assurance (QA): Responsible for reviewing the study protocol, monitoring the conduct of the study, and verifying data integrity.

Analytical Team: Responsible for conducting the required tests and analyses according to the approved protocol and recording all data accurately.

Storage and Facility Manager: Responsible for maintaining the stability chambers according to the specified conditions and ensuring that all samples are stored appropriately.

4) Procedure

4.1 Study Design:

1. Determine the objective of the stability study, including the specific characteristics of the vaccine product to be evaluated (e.g., potency, purity, sterility, and pH).
2. Select appropriate stability-indicating parameters and define the acceptance criteria for each parameter.
3. Identify the storage conditions to be tested, such as controlled room temperature, refrigeration, or freezing, based on the product’s intended use and regulatory guidelines.
4. Develop a detailed study protocol, including the number of batches to be tested, sampling time points, and analytical methods to be used.

4.2 Sample Preparation:

1. Prepare samples from representative batches according to the manufacturing process.
2. Ensure that samples are properly labeled with the batch number, storage conditions, and sampling time points.
3. Distribute samples into stability chambers with conditions set according to the study protocol.

4.3 Testing Schedule:

1. Perform initial testing on all samples to establish baseline data for the selected stability-indicating parameters.
2. Conduct follow-up testing at predetermined intervals (e.g., 1 month, 3 months, 6 months, 12 months) to evaluate the impact of storage conditions on the vaccine’s quality.
3. Document all test results and compare them with the predefined acceptance criteria to assess stability.

4.4 Data Analysis and Reporting:

1. Analyze data using appropriate statistical methods to evaluate trends over time and the product’s compliance with the acceptance criteria.
2. Prepare a stability study report summarizing the findings, conclusions, and recommended shelf life or storage conditions.
3. Submit the report for review by the QA team and any other relevant stakeholders.

4.5 Archiving and Record Keeping:

1. Ensure that all raw data, test results, and stability study reports are archived according to the organization’s data retention policy.
2. Maintain a backup of all digital records and ensure secure access to authorized personnel only.

5) Abbreviations, if any

QA: Quality Assurance

SOP: Standard Operating Procedure

6) Documents, if any

Stability Protocol Document: Document detailing the study design, objectives, and procedures.

Analytical Method Validation Report: Document verifying the accuracy, precision, and reliability of the analytical methods used in the study.

Stability Study Report: Final report summarizing the study findings and conclusions.

7) Reference, if any

ICH Q1A(R2): Stability Testing of New Drug Substances and Products

WHO Technical Report Series: Guidelines on Stability Evaluation of Vaccines

8) SOP Version

Version 1.0